Interestingly, resistance to gefitinib driven by MET amplification resulted in resistance to both CNX-2006 and CO-1686, with over 1000-fold drop in drug activity in HCC-827GR5 cells compared to parental cells [15]. The gene discussed is MET; the disease is hepatocellular carcinoma.